<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526045</url>
  </required_header>
  <id_info>
    <org_study_id>CAUY922A2101</org_study_id>
    <secondary_id>2006-002766-20</secondary_id>
    <nct_id>NCT00526045</nct_id>
  </id_info>
  <brief_title>Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients</brief_title>
  <official_title>A Phase I Dose Escalation, Multi-center, Open-label Study of AUY922 Administered IV on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies Including Phase II Expansion Arms in Patients With Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a phase I/II, open-label, multicenter study of AUY922 administered intravenously in&#xD;
      patients with advanced solid malignancies to determine the maximum tolerated dose. Phase II&#xD;
      expansion arms will investigate efficacy in patients with either HER2 positive or ER positive&#xD;
      locally advanced or metastatic breast cancer. Additional patients with advanced solid&#xD;
      malignancies will also be investigated in a separate expansion arm. Safety, pharmacokinetics&#xD;
      and pharmacodynamics will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safe dose of AUY922 when administered once a week</measure>
    <time_frame>54 weeks (MTD determination)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AUY922 administered once a week</measure>
    <time_frame>Baseline, and every 2 cycles (time to document tumor progression)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AUY922 and Pharmacodynamics by PET response, blood and tumor biomarkers at baseline and post-AUY922</measure>
    <time_frame>Baseline and every 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2 Positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ER+ breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUY922 2 mg/m2</intervention_name>
    <arm_group_label>ER+ breast cancer</arm_group_label>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_label>HER2 Positive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Dose-escalation and MTD dose expansion arm: Patients with histologically confirmed,&#xD;
             advanced malignant solid tumors whose disease has progressed on standard therapy or&#xD;
             for whom no standard therapy exists.&#xD;
&#xD;
             Breast cancer phase II expansion arms only:&#xD;
&#xD;
               1. Females patients with HER2 positive non-operable locally advanced or metastatic&#xD;
                  breast cancer must have:&#xD;
&#xD;
                    -  History of trastuzumab resistance, defined as either local or systemic&#xD;
                       disease progression on treatment with at least 8 weeks of a trastuzumab&#xD;
                       containing regimen.&#xD;
&#xD;
                    -  Received up to 3 prior anti HER2 based regimens (i.e. trastuzumab and/or&#xD;
                       lapatinib in combination with other agents) for metastatic disease&#xD;
&#xD;
                    -  Patients who develop metastases while receiving adjuvant or neo-adjuvant&#xD;
                       trastuzumab are eligible.&#xD;
&#xD;
                  HER2 positive patients, tumor/s must demonstrate HER2 over-expression based on&#xD;
                  either:&#xD;
&#xD;
                    -  Immunohistochemistry (IHC) at the 3+ level, or&#xD;
&#xD;
                    -  IHC 2+ confirmed by fluorescence in-situ hybridization (FISH). Tumors tested&#xD;
                       by FISH must be positive by the specific FISH assay for the amplification of&#xD;
                       HER2.&#xD;
&#xD;
               2. Female patients with ER positive non-operable locally advanced or metastatic&#xD;
                  breast cancer patients who received standard sequence lines of endocrine therapy&#xD;
                  and whose disease has progressed on at least one and up to 3 lines of endocrine&#xD;
                  and/or cytotoxic therapy for advanced disease.&#xD;
&#xD;
          2. All patients must have at least one measurable lesion as defined by RECIST. Irradiated&#xD;
             lesions are only evaluable for disease progression.&#xD;
&#xD;
          3. All patients must have progressive disease before entering the study&#xD;
&#xD;
          4. Age ≥ 18 years.&#xD;
&#xD;
          5. World Health Organization (WHO) Performance Status of ≤ 2.&#xD;
&#xD;
          6. Life expectancy of ≥ 12 weeks.&#xD;
&#xD;
          7. Absolute Neutrophil Count (ANC) 1.5 x 109/L; hemoglobin (Hgb) 9 g/dl; platelets (plt)&#xD;
             100 x 109/L; potassium, calcium, magnesium and phosphorus within normal limits or&#xD;
             correctable with supplements; AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal&#xD;
             (ULN) or ≤ 5.0 x ULN if liver metastases are present; serum bilirubin 1.5 x ULN; serum&#xD;
             albumin &gt; 2.5g/dl and serum creatinine 1.5 x ULN or 24-hour clearance 50 ml/min&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients with CNS metastasis which are:&#xD;
&#xD;
               -  Symptomatic or&#xD;
&#xD;
               -  Require treatment for symptom control and/or&#xD;
&#xD;
               -  Growing&#xD;
&#xD;
             Note: patients without clinical signs or symptoms of CNS involvement are not required&#xD;
             to have a CT/MRI of the brain&#xD;
&#xD;
          2. Prior treatment with any HSP90 or HDAC inhibitor compound.&#xD;
&#xD;
          3. Patient who received systemic anti-cancer treatment prior to the first dose of AUY922&#xD;
             within the following time frames:&#xD;
&#xD;
               -  Chemotherapy within 4 weeks&#xD;
&#xD;
               -  Radiotherapy within 4 weeks&#xD;
&#xD;
               -  Palliative radiotherapy: within 2 weeks&#xD;
&#xD;
               -  Trastuzumab treatment within 4 weeks&#xD;
&#xD;
               -  Nitrosoureas, mitomycin and monoclonal antibodies (except trastuzumab): within 6&#xD;
                  weeks&#xD;
&#xD;
               -  Any continuous-dosing (i.e. daily dosing, every-other-day dosing, Monday-&#xD;
                  Wednesday-Friday dosing, weekly etc) of systemic anticancer treatment for which&#xD;
                  the recovery period is not known, or investigational drugs (i.e. targeted agents)&#xD;
                  within a duration of ≤ 5 half lives of the agent and their active metabolites (if&#xD;
                  any)&#xD;
&#xD;
          4. Patients who have not recovered from side effects of previous systemic anticancer&#xD;
             therapy to less than grade 2 CTCAE prior to the first dose.&#xD;
&#xD;
          5. Pregnant or lactating women.&#xD;
&#xD;
          6. Cardia exclusion criteria:&#xD;
&#xD;
               -  History (or family history) of long QT syndrome.&#xD;
&#xD;
               -  Mean QTc ≥ 450 msec on screening ECG&#xD;
&#xD;
               -  History of clinically manifest ischemic heart disease including myocardial&#xD;
                  infarction, stable or unstable angina, coronary arteriography or cardiac stress&#xD;
                  testing/imaging with findings consistent with coronary occlusion or infarction, ≤&#xD;
                  6 months prior to study start.&#xD;
&#xD;
               -  History of heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by&#xD;
                  MUGA or ECHO&#xD;
&#xD;
          7. Known diagnosis of HIV infection (HIV testing is not mandatory).&#xD;
&#xD;
          8. Acute or chronic liver disease, acute or chronic renal disease or other concurrent&#xD;
             severe and/or uncontrolled medical conditions (e.g. uncontrolled diabetes, active or&#xD;
             uncontrolled infection) that could cause unacceptable safety risks or compromise&#xD;
             compliance with the protocol.&#xD;
&#xD;
          9. Cardiac exclusion criteria:&#xD;
&#xD;
        Mean QTc ≥ 450 msec on screening ECG and clinically significant ECG abnormalities including&#xD;
        one or more of the following: left bundle branch block (LBBB), right bundle branch block&#xD;
        (RBBB) with left anterior hemiblock (LAHB). ST segment elevations or depressions &gt; 1mm, or&#xD;
        2nd (Mobitz II) or 3rd degree AV block; clinically significant ECG abnormalities including&#xD;
        one or more of the following: left bundle branch block (LBBB), right bundle branch block&#xD;
        (RBBB) with left anterior hemiblock (LAHB). ST segment elevations or depressions &gt; 1mm, or&#xD;
        2nd (Mobitz II) or 3rd degree AV block.&#xD;
&#xD;
        History (or family history) of long QT syndrome, heart failure or left ventricular (LV)&#xD;
        dysfunction (LVEF ≤ 45%) by MUGA or ECHO, history of clinically manifest ischemic heart&#xD;
        disease including myocardial infarction, stable or unstable angina, coronary arteriography&#xD;
        or cardiac stress testing/imaging with findings consistent with coronary occlusion or&#xD;
        infarction, ≤ 6 months prior to study start; history or presence of atrial fibrillation,&#xD;
        atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de&#xD;
        Pointes.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA/ University of California Los Angeles UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University Med College of GA</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine-Siteman Cancer Ctr Dept. of Siteman Cancer Ctr.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute Clinical Trials Office</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med.Onc(2)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center InstituteForDrugDevelopment(3)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8324</url>
    <description>Resutls for CAUY922A2101 on the Novartis clinical trials website</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <disposition_first_submitted>August 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 26, 2020</disposition_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AUY922</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Phase I/II</keyword>
  <keyword>Advanced Solid malignancies (Phase I)</keyword>
  <keyword>Breast Cancer ( Phase II )</keyword>
  <keyword>HER2+</keyword>
  <keyword>ER+</keyword>
  <keyword>HSP90</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

